EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE‐related immune thrombocytopenia

Dafna Brik-Simon, Orly Efros, Yoel Levinsky, Gil Amarilyo, Irit Tirosh, Sarina Levy-Mendelovich iD, Orna Steinberg-Shemer iD, Shai Izraeli, Joanne Yacobovich, Oded Gilad iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30911 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Dafna Brik-Simon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Lupus Erythematosus, Systemic, Thrombocytopenia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric immune thrombocytopenia (ITP) may precede systemic autoimmune disorders. In adolescent patients with ITP, routine screening for systemic lupus erythematosus (SLE) may be performed by testing for antinuclear antibody (ANA) titer. Hydroxychloroquine (HCQ) is a safe and effective immunomodulatory drug in patients with SLE but rarely used in ITP. We analyzed the platelet count response and safety of HCQ in treating pediatric patients with SLE‐related ITP.

Methods

A retrospective study including pediatric patients with ITP and definite or incomplete SLE, who were treated with HCQ during 2010‐2021. SLE was defined by ANA titer ≥ 1:160 as measured by immunofluorescence and ≥10 points according to the 2019 EULAR/ACR 2019 classification criteria, while patients with incomplete SLE achieved a score < 10. Complete response (CR) of the platelet count was defined as platelet count > 100 × 10 9 /L; partial response (PR) as platelet count 30‐100 × 10 9 /L and exceeding ≥ twice baseline counts.

Results

Of the 17 patients included (median age 15.5 years; IQR 3.6), 15 (88.2%) were female, 13 had definite SLE, and four had incomplete SLE. HCQ was initiated at a median of 17 months after ITP diagnosis with a median platelet count of 38 × 10 9 /L (IQR 28). At 8 weeks, 8 (47.1%) patients responded, including 6 (35.3%) achieving CR. After one year, the overall response was 82.4%, with the remaining patients having stable platelet counts requiring no additional ITP therapy. The response was maintained at a median follow‐up of 42 months. No adverse effects to HCQ were noted.

Conclusion

Pediatric patients with SLE‐related ITP may benefit from treatment with HCQ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicLupus Erythematosus, SystemicThrombocytopeniaAdolescentHumansFemaleChildMaleHydroxychloroquineRetrospective Studies

Stichwörter der Autor:innen

ANAITPSLEhydroxychloroquinepediatrics

Substanzen

Hydroxychloroquine

Autor:innen und Institutionen

  • Department of Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, Ramat Gan, Israel.
  • Amalia Biron Research Institute of Thrombosis and Hemostasis, School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • Pediatric Rheumatology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Sarina Levy-Mendelovich, Orna Steinberg-Shemer, Oded Gilad

Zitieren

APA

Brik-Simon, D., Efros, O., Levinsky, Y., Amarilyo, G., Tirosh, I., Levy-Mendelovich, S., Steinberg-Shemer, O., Izraeli, S., Yacobovich, J., & Gilad, O. (2024). Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE‐related immune thrombocytopenia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30911

Vancouver

Brik-Simon D, Efros O, Levinsky Y, Amarilyo G, Tirosh I, Levy-Mendelovich S, et al. Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE‐related immune thrombocytopenia. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30911

BibTeX
@article{BrikSimon2024,
  author = {Brik-Simon, Dafna and Efros, Orly and Levinsky, Yoel and Amarilyo, Gil and Tirosh, Irit and Levy-Mendelovich, Sarina and Steinberg-Shemer, Orna and Izraeli, Shai and Yacobovich, Joanne and Gilad, Oded},
  title = {Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE‐related immune thrombocytopenia},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30911}
}
Kostenlos starten →